Invion Ltd. · ASX:IVX
Invion — Shareholder Meeting (November 2017)
24 slides from Invion's shareholder meeting presentation, Nov 30, 2017
Slide 1: Invion
INVION
Slide 2: Chairman's Presentation 2017 AGM
CHAIRMAN’S PRESENTATION 2017 AGM
Slide 3: Invion Strategy in 2017
INVION STRATEGY IN 2017 AIM: OUTCOME: Identify and pursue opportunities to Licence to develop and commercialise reshape and enhance the company’s Photosoft™ for the treatment of cancers pipeline and business growth Agreement that provides non-dilutive funding for asset development
Slide 4: Strategic Transaction with the Cho Group
R&D Services Agreement: Invion will conduct clinical development of Photosoft™ globally, STRATEGIC leveraging the Company’s expertise. The Cho Group will provide non- dilutive funding for R&D and clinical TRANSACTION trials as part of a global development strategy for the asset 1 3 WITH THE CHO GROU
Slide 5: What is Photo Dynamic Therapy (PDT)?
WHAT IS PHOTO DYNAMIC THERAPY (PDT)? Use of light to destroy cancerous cells or other abnormal tissue When exposed to specific wavelengths of light, photosensitizing agents produce a form of oxygen that causes destruction of nearby cells without damaging nearby tissue Wavelength determines how far t
Slide 6: How PDT Works
Photosensitizing 1 HOW PDT agent is taken (by mouth) or given (intravenously) The agent circulates through 2 WORKS the body and concentrates at the site of the tumour Light of specific wavelengths is 3 shone on the body which activates the reaction in the tumour The tumour is 4 selectively destroyed
Slide 7: PDT in Practice
PDT IN PRACTICE PDT IS USUALLY PERFORMED AS AN OUTPATIENT PROCEDURE There are a number of clinics throughout Australia that offer PDT therapy for the treatment of superficial skin cancers, and sunspots, including solar keratoses PDT may be repeated and may be used with other therapies, such as surge
Slide 8: First Generation Photosensitizers
PDT therapy became ‘mainstream’ in Variants of 1995 with the FDA PhotofrinⓇ Tended to remain approval of Photofrin were in the body for Ⓡ (porfimer sodium) subsequently long periods for treatment developed in of esophageal clinical trials cancer HOWEVER FIRST Does not absorb GENERATION PDT Fat solub
Slide 9: Second Generation Photosensitizers
Strong absorption Water soluble and longer Largely with good chlorophyll wavelengths tissue allowing deeper based distribution penetration of tissues Low circulation BETTER times so patients Different TUMOR are not left chemistry SPECIFICITY vulnerable to SECOND sunlight damage GENERATION PHOTOSENSI
Slide 10: New Wave of Interest with Tookad
NEW WAVE OF INTEREST WITH TOOKAD STEBA BIOTECH CONDUCTED PH III IN 208 “Localised, low-risk prostate cancer can be PATIENTS WITH LOW-RISK PROSTATE CANCER: treated in a way that not only preserves genitourinary function but also results in a TOOKAD ACTIVE lower progression rate, a greater chance of G
Slide 11: New Generation Photo Dynamic Therapy: Photosoft
NEW GENERATION PHOTO DYNAMIC THERAPY: PHOTOSOFT™ Invion to in-licence asset based on patented PDT agent Photosoft™ Targeted to address limitations of 1st Generation PDT therapies Uses a laser light activation method based on a short, pulsating Near Infrared (NIR) wavelengths High photodynamic effici
Slide 12: Photosoft
PHOTOSOFT™ Chlorophyll-based PDT photosensitiser Complex of chlorin and chlorophyllin ACTIVATES AT MULTIPLE SENSITIVITY RANGES ACROSS A BROAD SPECTRUM
Slide 13: Localised Prostate Cancer: The State of Play
LOCALISED PROSTATE CANCER: THE STATE OF PLAY INCREASING NUMBERS OF MEN ARE CHOOSING ACTIVE SURVEILLANCE OVER SURGERY OR RADIOTHERAPY BECAUSE OF THE RISKS OF THESE TREATMENTS Active surveillance was ~6% of US patients 15 years ago, now 40% Surgery and radiotherapy are radical treatments associated wi
Slide 14: Early Studies of Photosoft Conducted in Australia
EARLY STUDIES OF PHOTOSOFT™ CONDUCTED IN AUSTRALIA PHASE I | PROSTATE CANCER 2013 2017 o Photosoft™ was administered to 68 prostate cancer patients by o A second Phase I was completed by Donald Murphy in Urologist Donald Murphy and collaborators collaboration with Monash University o Results for 26
Slide 15: A New Wave: Immunotherapy and PDT
A NEW WAVE: IMMUNOTHERAPY AND PDT Immune response is important in the control of tumour 2013 2017 growth o Photosoft was administered to 68 prostate cancer patients by o A second Phase I was completed by Donald Murphy in Urologist Donald Murphy and collaborators collaboration with Monash University
Slide 16: Phase I Prostate Cancer Data
PHASE I PROSTATE CANCER DATA 86 proteins relating to immune responses were observed Proteins relating to certain immune response pathways are enriched and were significantly over-represented within the dataset
Slide 17: Advantages of NGPDT and Photosoft
ADVANTAGES OF NGPDT AND PHOTOSOFT™ The immune response observed by Murphy in the Phase I provides potential advantages over other water-soluble PDT therapies such as TookadⓇ There is a growing body of knowledge that PDT has the potential to generate an anti-cancer immune response TookadⓇ Ph III succ
Slide 18: PDT Therapies Target Early-Stage Treatment
TARGETS Skin cancers including melanoma, squamous cell carcinoma & basal PDT THERAPIES cell carcinoma TARGET EARLY-STAGE Lung cancer TREATMENT AS NON-INVASIVE Prostate or Ovarian cancer AND REPEATABLE
Slide 19: First Steps: Funded with Non-Dilutive Capital
FIRST STEPS: FUNDED WITH NON-DILUTIVE Establish Scientific Explore short term Develop ovarian CAPITAL Advisory Board, opportunities for cancer strategy as and timing/ costs of treatment of skin the next clinical Phase II/ III clinical cancers and other opportunity for trials in prostate disorders Ph
Slide 20: Acquisition/Licensing Opportunities
ACQUISITION/ LICENSING OPPORTUNITIES INV103 (Cpn10) INV102 (Nadolol) INV104 (Zafirlukast) Current assets have completed programmed clinical development Management remains committed to licensing the assets
Slide 21: Management Team
MANAGEMENT TEAM CURRENT Dr Greg Collier Dr Mitchell Glass Melanie Farris (Invion, Inc). Interim Executive Head of Chair Chief Medical Operations and Officer Company Secretary
Slide 22: Management Team Post-Transaction
MANAGEMENT TEAM POST-CURRENT TRANSACTION Mr Thian Chew Dr Greg Collier Dr Mitchell Glass Melanie Farris Other Chief Executive (Invion, Inc). Board changes Non-Executive Head of Officer anticipated to Chairman Chief Medical Operations and occur in 2018 Officer Company Secretary
Slide 23: Company Snapshot and Impact of Transaction
COMPANY SNAPSHOT AND IMPACT OF TRANSACTION The effect of the proposed transaction on the Overall ownership structure of the Company after capital structure of the Company completion of the Underwritten Rights Issue Number of Percentage of Shares issued capital Shares on issue at the date of the Noti
Slide 24: Invion
INVION